- Home
- BRBI vs RCKT Comparison
BRBI vs RCKT Comparison
Compare BRBI & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRBI | RCKT |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | Brazil | United States |
| Employees | 188 | 202 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.0M | 534.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BRBI | RCKT |
|---|---|---|
| Price | $15.93 | $3.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $29.73 |
| AVG Volume (30 Days) | 3.9K | ★ 4.3M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.24 | $64.28 |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.54 | $2.19 |
| 52 Week High | $67.01 | $8.26 |
Technical Indicators
Market Signals| Indicator | BRBI | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 49.31 |
| Support Level | $13.77 | $2.95 |
| Resistance Level | $16.46 | $4.08 |
| Average True Range (ATR) | 0.29 | 0.20 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 78.80 | 72.19 |
Price Performance
Historical ComparisonAbout BRBI BRBI BR Partners S.A. ADSs
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.